

COMPANY FACT SHEET

Headquarters

Magnus Medical, Inc.
1350 Old Bayshore Highway, Suite 600
Burlingame, CA 94010

Employees

40 employees

Financing

\$25M in Series A financing co-led by Jazz Venture Partners and Red Tree Venture Capital.

Magnus Medical

A privately held therapeutic neuromodulation company that has developed the SAINT® neuromodulation system, a groundbreaking, rapid-acting therapy for treatment-resistant depression.

The company announced the commercial launch of the SAINT neuromodulation system in April 2024. Granted Breakthrough Device Designation and 510(k) clearance by the U.S. Food & Drug Administration (FDA) for the treatment of major depressive disorder (MDD) in adults who have failed to achieve satisfactory improvement from prior antidepressant medications in the current episode, SAINT therapy has led to dramatic improvements in people's symptoms of severe depression in a [clinical setting](#).

Technology and Clinical Results

SAINT therapy uses structural and functional MRI scans to inform a proprietary algorithm that identifies the optimal anatomic target for focused neurostimulation in people with MDD. SAINT was developed at the Stanford Brain Stimulation Lab and licensed exclusively to Magnus Medical in October 2021 for commercialization.

For the first time, advanced tools for processing MRI-based images of the brain are used to steer a specialized, high-dose pattern of magnetic pulses to induce neurons to fire. This stimulation modifies activity in brain networks related to depression, changing the brain's circuitry to more effectively treat MDD.

In a double-blinded randomized controlled trial (RCT) evaluating SAINT, 14 people received active treatment and another 15 people received sham (placebo) treatment. The results show that 79% of people in the active treatment arm entered remission following

the five-day treatment protocol, compared to people in the sham arm, where only 13% entered remission.¹

The SAINT protocol has additionally been studied in non-RCT (open-label) studies. Overall, the therapy has been shown to be effective in the treatment of MDD, with approximately 80-90% of patients achieving remission of depression symptoms following the five-day treatment protocol.²

Company Spokespeople

Christian Gormsen, president and CEO

Brandon Bentzley, M.D., Ph.D., co-founder and CSO

#

Media Contact:

Amy Cook

amy@magnusmed.com

925.222.5094

¹ Cole EJ, Phillips AL, Bentzley BS, et al. "Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial." *The American Journal of Psychiatry*. Oct 29, 2021.

² Cole EJ, Phillips AL, Bentzley BS, et al. "Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression." *The American Journal of Psychiatry*. 2020;177(8):716–726.